BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12767603)

  • 21. Synthesis and biological activity of olomoucine II.
    Krystof V; Lenobel R; Havlícek L; Kuzma M; Strnad M
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3283-6. PubMed ID: 12392733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
    Oh CH; Lee SC; Lee KS; Woo ER; Hong CY; Yang BS; Baek DJ; Cho JH
    Arch Pharm (Weinheim); 1999 Jun; 332(6):187-90. PubMed ID: 10399486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
    Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
    Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.
    Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L
    Bioorg Med Chem Lett; 1998 Apr; 8(7):793-8. PubMed ID: 9871543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.
    Carraro F; Pucci A; Naldini A; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Manetti F; Botta M
    J Med Chem; 2004 Mar; 47(7):1595-8. PubMed ID: 15027847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
    Trávnícek Z; Krystof V; Sipl M
    J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T
    Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2).
    Yue EW; Higley CA; DiMeo SV; Carini DJ; Nugiel DA; Benware C; Benfield PA; Burton CR; Cox S; Grafstrom RH; Sharp DM; Sisk LM; Boylan JF; Muckelbauer JK; Smallwood AM; Chen H; Chang CH; Seitz SP; Trainor GL
    J Med Chem; 2002 Nov; 45(24):5233-48. PubMed ID: 12431051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
    Jorda R; Havlíček L; Šturc A; Tušková D; Daumová L; Alam M; Škerlová J; Nekardová M; Peřina M; Pospíšil T; Široká J; Urbánek L; Pachl P; Řezáčová P; Strnad M; Klener P; Kryštof V
    J Med Chem; 2019 May; 62(9):4606-4623. PubMed ID: 30943029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
    De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
    Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines.
    Li J; Zhao YF; Zhao XL; Yuan XY; Gong P
    Arch Pharm (Weinheim); 2006 Nov; 339(11):593-7. PubMed ID: 17036367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.
    Lamie PF
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3093-3097. PubMed ID: 27189674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
    Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres.
    Jorda R; Paruch K; Krystof V
    Curr Pharm Des; 2012; 18(20):2974-80. PubMed ID: 22571665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological activity of 8-azapurine and pyrazolo[4,3-d]pyrimidine analogues of myoseverin.
    Krystof V; Moravcová D; Paprskárová M; Barbier P; Peyrot V; Hlobilková A; Havlícek L; Strnad M
    Eur J Med Chem; 2006 Dec; 41(12):1405-11. PubMed ID: 16996651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel pyrazolo[3,4-d]pyrimidine-based inhibitors of Staphlococcus aureus DNA polymerase III: design, synthesis, and biological evaluation.
    Ali A; Taylor GE; Ellsworth K; Harris G; Painter R; Silver LL; Young K
    J Med Chem; 2003 May; 46(10):1824-30. PubMed ID: 12723946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases.
    Gangjee A; Yang J; Ihnat MA; Kamat S
    Bioorg Med Chem; 2003 Nov; 11(23):5155-70. PubMed ID: 14604679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.
    Abbas SE; Aly EI; Awadallah FM; Mahmoud WR
    Chem Biol Drug Des; 2015 May; 85(5):608-22. PubMed ID: 25318985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.